• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钩端螺旋体疫苗效力测试的国际监管要求。圆桌会议:当前要求及协调机会。

International regulatory requirements for Leptospira vaccine potency testing. Roundtable: current requirements and opportunity for harmonization.

作者信息

Draayer Hans A, Bruckner Lukas, Peña-Moctezuma Alejandro de la, Srinivas Geetha

机构信息

Gourdneck View Consulting, LLC, Portage, MI 49002, USA.

出版信息

Biologicals. 2013 Sep;41(5):305-7. doi: 10.1016/j.biologicals.2013.06.008. Epub 2013 Jul 23.

DOI:10.1016/j.biologicals.2013.06.008
PMID:23890730
Abstract

Progress continues to be made in the ongoing efforts to replace, reduce, or refine the use of laboratory animals for Leptospira vaccine potency testing in certain markets/regions. Leptospira-containing vaccines, as with many veterinary vaccines, are manufactured and distributed both on a regional basis by local manufacturers and internationally by large multinational firms. Three general scenarios exist for the international testing and distribution of veterinary vaccines including: 1) the importing country recognizes the country of origin's testing and batch release data with no additional testing; 2) the importing country requires the manufacturer to conduct a specific potency assay based on the current importing market's regulations for the importing country or 3) the importing country requires retesting of the product in country prior to distribution. Scenarios 2 and 3 both have the potential to significantly increase the usage of laboratory animals for what may be considered redundant testing. Specific requirements for the importation of Leptospira vaccines in the United States, Europe, and Mexico were presented as well as efforts to reduce the use of laboratory animal testing through the availability of internationally recognized tests.

摘要

在某些市场/地区,为钩端螺旋体疫苗效力测试而进行的替代、减少或优化实验动物使用的持续努力仍在取得进展。与许多兽用疫苗一样,含钩端螺旋体的疫苗由当地制造商在区域范围内生产和分销,也由大型跨国公司在国际上生产和分销。兽用疫苗的国际测试和分销存在三种一般情况,包括:1)进口国认可原产国的测试和批次放行数据,无需额外测试;2)进口国要求制造商根据当前进口市场对进口国的规定进行特定的效力测定;或3)进口国要求在产品分销前在国内重新进行测试。情况2和情况3都有可能显著增加用于可能被视为冗余测试的实验动物的使用量。介绍了美国、欧洲和墨西哥对钩端螺旋体疫苗进口的具体要求,以及通过提供国际认可的测试来减少实验动物测试使用的努力。

相似文献

1
International regulatory requirements for Leptospira vaccine potency testing. Roundtable: current requirements and opportunity for harmonization.钩端螺旋体疫苗效力测试的国际监管要求。圆桌会议:当前要求及协调机会。
Biologicals. 2013 Sep;41(5):305-7. doi: 10.1016/j.biologicals.2013.06.008. Epub 2013 Jul 23.
2
USDA regulatory guidelines and practices for veterinary Leptospira vaccine potency testing.美国农业部关于兽用钩端螺旋体疫苗效力测试的监管指南与实践。
Biologicals. 2013 Sep;41(5):298-302. doi: 10.1016/j.biologicals.2013.06.005. Epub 2013 Jul 6.
3
European regulatory framework and practices for veterinary Leptospira vaccine potency testing.欧洲兽用钩端螺旋体疫苗效力测试的监管框架与实践
Biologicals. 2013 Sep;41(5):303-4. doi: 10.1016/j.biologicals.2013.06.014. Epub 2013 Jul 22.
4
Report on the international workshop on alternative methods for Leptospira vaccine potency testing: state of the science and the way forward.钩端螺旋体疫苗效力检测替代方法国际研讨会报告:科学现状与未来发展方向
Biologicals. 2013 Sep;41(5):279-94. doi: 10.1016/j.biologicals.2013.06.013. Epub 2013 Jul 23.
5
Development and validation of a serological potency test for the release of Leptospira vaccines--requirements in the European Union.
Biologicals. 2013 Sep;41(5):325-9. doi: 10.1016/j.biologicals.2013.06.011. Epub 2013 Aug 1.
6
Opportunities and strategies to further reduce animal use for Leptospira vaccine potency testing.进一步减少用于钩端螺旋体疫苗效力测试的动物使用量的机会和策略。
Biologicals. 2013 Sep;41(5):332-7. doi: 10.1016/j.biologicals.2013.06.006. Epub 2013 Jul 24.
7
Product-specific validation of a serological potency test for release of Leptospira vaccines in the European Union.欧盟用于钩端螺旋体疫苗放行的血清学效力试验的产品特异性验证。
Biologicals. 2013 Sep;41(5):330-1. doi: 10.1016/j.biologicals.2013.06.004. Epub 2013 Jul 10.
8
Development of in vitro assays for measuring the relative potency of leptospiral bacterins containing serogroups canicola, grippotyphosa, icterohaemorrhagiae, and pomona.用于测定包含犬型、爪哇型、出血性黄疸型和波摩那型血清群的钩端螺旋体菌苗相对效力的体外检测方法的开发。
Biologicals. 2013 Sep;41(5):308-14. doi: 10.1016/j.biologicals.2013.06.007. Epub 2013 Jul 16.
9
Expansion of the in vitro assay for Leptospira potency testing to other serovars: case study with Leptospira Hardjo.将钩端螺旋体效力测试的体外试验扩展至其他血清型:以哈焦钩端螺旋体为例的案例研究
Biologicals. 2013 Sep;41(5):323-4. doi: 10.1016/j.biologicals.2013.06.003. Epub 2013 Jul 6.
10
Development of Leptospira in vitro potency assays: EU/industry experience and perspectives.钩端螺旋体体外效力测定的发展:欧盟/行业经验与观点。
Biologicals. 2013 Sep;41(5):315-22. doi: 10.1016/j.biologicals.2013.06.012. Epub 2013 Jul 16.

引用本文的文献

1
Replacement of in vivo leptospirosis vaccine potency testing in the United States.在美国替代活体钩端螺旋体病疫苗效力检测。
Biologicals. 2022 Jul;78:36-44. doi: 10.1016/j.biologicals.2022.05.001. Epub 2022 Jun 24.